Publikationen von Astrid Sydow

Anglada-Huguet, M.; Endepols, H.; Sydow, A.; Hilgers, R.; Neumaier, B.; Drzezga, A.; Kaniyappan, S.; Mandelkow, E.; Mandelkow, E.-M.: Reversal of Tau-dependent cognitive decay by blocking adenosine A1 receptors: Comparison of transgenic mouse models with different levels of tauopathy. International Journal of Molecular Sciences 24 (11), 9260 (2023)

Green, C.; Sydow, A.; Vogel, S.; Anglada-Huguet, M.; Wiedermann, D.; Mandelkow, E.; Mandelkow, E.-M.; Höhn, M.: Functional networks are impaired by elevated tau-protein but reversible in a regulatable Alzheimer's disease mouse model. Molecular Neurodegeneration 14, 13 (2019)

Decker, J. M.; Krüger, L.; Sydow, A.; Dennissen, F.; Siskova, Z.; Mandelkow, E.; Mandelkow, E.-M.: The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity. EMBO Reports 17 (4), S. 552 - 569 (2016)

Dennissen, F. J. A.; Anglada-Huguet, M.; Sydow, A.; Mandelkow, E.; Mandelkow, E.-M.: Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau δK280. Proceedings of the National Academy of Sciences of the United States of America 113 (41), S. 11597 - 11602 (2016)

Sydow, A.; Hochgräfe, K.; Koenen, S.; Cadinu, D.; Matenia, D.; Petrova, O.; Joseph, M.; Dennissen, F. J.; Mandelkow, E.-M.: Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD. Acta Neuropathologica Communications 4, 17 (2016)

Hochgräfe, K.; Sydow, A.; Mandelkow, E.-M.: Regulatable transgenic mouse models of Alzheimer disease: Onset, reversibility and spreading of Tau pathology. FEBS Journal 280 (18), S. 4371 - 4381 (2013)

Van der Jeugd, A.; Hochgräfe, K.; Ahmed, T.; Decker, J. M.; Sydow, A.; Hofmann, A.; Wu, D.; Messing, L.; Balschun, D.; D'Hooge, R. et al.; Mandelkow, E.-M.: Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathologica 123 (6), S. 787 - 805 (2012)